EC Number |
Inhibitors |
Structure |
---|
1.5.3.13 | 1,12-diaminododecane |
1,12-diaminododecane derivatives could represent good candidates for the development of novel highly specific mPAO inhibitors |
|
1.5.3.13 | 1,8-diaminooctane |
competitive versus the polyamine |
|
1.5.3.13 | 6,6'-[ethane-1,2-diyldi(piperidine-4,1-diyl)]bis[N-[(2-methoxyphenyl)methyl]hexan-1-amine] |
17fold selectivity for spermine oxidase over polyamine oxidase |
|
1.5.3.13 | Chlorhexidine |
- |
|
1.5.3.13 | guazatine |
- |
|
1.5.3.13 | MDL72527 |
- |
|
1.5.3.13 | MDL72527 |
irreversible. In addition to the covalent adduct, a second MDL72527 molecule is bound in the active site. Binding of MDL72527 is accompanied by altered conformations in the APAO backbone |
|
1.5.3.13 | methoctramine |
120fold selectivity for spermine oxidase over polyamine oxidase |
|
1.5.3.13 | more |
no inhibition at pH 7.5: 1,8-diaminooctane. Comparative study on murine PAO (mPAO) and SMO (mSMO) inhibition. The different behaviour displayed by 1,12-diaminododecane towards mPAO and mSMO reveals the occurrence of basic differences in the ligand binding mode of the two enzymes, the first enzyme interacting mainly with substrate secondary amino groups and the second one with substrate primary amino groups. The data provide the basis for the development of novel and selective inhibitors able to discriminate between mammalian SMO and PAO activities |
|
1.5.3.13 | more |
no inhibitory activity: N-(3-aminopropyl)-N-2-propynyl-1,4-butanediamine and N-[3-(2-propynylamino)propyl]-1,4-butanediamine |
|